Bracken R B, Johnson D E, Rodriquez L, Samuels M L, Ayala A
Urology. 1977 Feb;9(2):161-3. doi: 10.1016/0090-4295(77)90187-x.
Twenty-six patients with superficial Stage O or A transitional cell carcinoma of the urinary bladder, whose lesions were not amenable to transurethral resection, received bleomycin sulfate intravesically at weekly intervals for eight treatments. Five different drug regimens were tried, and the optimal concentration appeared to be 60 units dissolved in 30 cc. of sterile water. Serum determinations failed to reveal any significant absorption. There was a 27% complete response rate in patients with small tumor burdens. An additional 9% had partial responses which allowed the tumors to be readily managed transurethrally. However, no patients with extensive superficial tumor showed complete response to therapy. Although belomycin used intravesically is active against transitional cell carcinoma, the current cost of the drug precludes its routine use and restricts it to situations in which other agents are contraindicated.
26例膀胱浅表性O期或A期移行细胞癌患者,其病变无法经尿道切除,每周接受1次膀胱内注射硫酸博来霉素,共治疗8次。尝试了5种不同的给药方案,最佳浓度似乎是60单位溶解于30毫升无菌水中。血清检测未发现任何明显吸收。肿瘤负荷较小的患者完全缓解率为27%。另外9%的患者有部分缓解,使得肿瘤易于经尿道处理。然而,没有广泛浅表肿瘤患者对治疗表现出完全缓解。虽然膀胱内使用博来霉素对移行细胞癌有活性,但该药物目前的成本使其无法常规使用,仅限于其他药物禁忌的情况。